The FLuorometholone as Adjunctive MEdical Therapy for Trachomatous Trichiasis Surgery (FLAME) Trial: Study Design
Mohammed, A. A.; Abashawl, A.; Dodson, S.; Alemayehu, W.; Gemechu, A.; Mengesha, A. A.; Kumsa, D.; Succar, T.; Chen, Y.; McWilliams, K.; Bunya, V. Y.; Maguire, M. G.; Burton, M. J.; Ying, G.-s.; Kempen, J. H.
Show abstract
PurposeTo report the design of FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial. DesignParallel design, double-masked, placebo-controlled clinical trial with 1:1 randomization to fluorometholone 0.1% eyedrops twice daily or placebo twice daily for four weeks in eyes undergoing trachomatous trichiasis (TT) surgery; assessing the efficacy, safety, and cost-effectiveness of fluorometholone 0.1% in preventing recurrent postoperative trichiasis. MethodsUp to 2500 eligible persons with trachomatous trichiasis (TT) undergoing lid rotation surgery will be enrolled in Jimma zone, Ethiopia. Participants, surgeons, study field staff, and study supervisors leading operational aspects of the trial are masked to treatment assignment. Randomization is stratified by surgeon, which simultaneously stratifies by the district. The study visits are at baseline/enrollment, at four-week post-enrollment, six months, and one year (study exit). The primary outcome is cumulative one-year postoperative TT (PTT) incidence, defined as: [≥]1 lashes touching the globe, evidence of epilation, and/or repeat TT surgery. Secondary postoperative outcomes include number of trichiatic lashes, location thereof (touching the cornea or not), evidence of post-operative epilation, entropion, changes in corneal opacity, IOP elevation, need for cataract surgery, visual acuity change from baseline, eyelid contour abnormality, granuloma, eyelid closure defect, and occurrence of adverse events. Health economic analyses center on calculating the incremental cost per case of PTT avoided by fluorometholone treatment. ConclusionThe FLAME Trial is designed to provide evidence of the efficacy, safety, and cost-effectiveness of adjunctive topical peri-/postoperative fluorometholone 0.1% therapy with trichiasis surgery, which is hypothesized to reduce the risk of recurrent trichiasis while being acceptably safe. Trial Registration: ClinicalTrials.gov # NCT04149210
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- UVESCREEN1: A randomised feasibility study of imaging-based uveitis screening for children with juvenile idiopathic arthritis- Study Protocol 94%
- The evaluation of a web‐based tool for measuring the uncorrected visual acuity and refractive error in keratoconus eyes: a prospective open‐label method comparison study 94%
- Sociodemographic predictors of acute corneal hydrops in patients with unstable keratoconus 94%
Similar papers in this journal
Similar papers in this journal
- Diagnostic Performance of Deep Learning in Infectious Keratitis: A Systematic Review and Meta-Analysis Protocol 94%
- Prevalence, incidence and risk factors for myopia among urban and rural children in southern China: protocol for a school-based cohort study 94%
- Functional changes of visual cortex in pre- and post- operative intermittent exotropia patients: study protocol for a non-randomized case-control clinical trial 92%
Similar papers in this journal
- Risk Model for Intraoperative Complication during Cataract Surgery Based on Data from 900,000 Eyes – Previous Intravitreal Injection is a Risk Factor 93%
- Argon Laser Photocoagulation for Treatment of Presumed Trematode-induced Granulomatous Anterior Uveitis in Children 93%
- Automated Expert-level Scleral Spur Detection and Quantitative Biometric Analysis on the ANTERION Anterior Segment OCT System 92%
Similar papers in this journal
- The learning curve of murine subretinal injection among clinically trained ophthalmic surgeons 93%
- A Tear-Based Approach for Rapid Identification of Bacterial Pathogens in Corneal Ulcers Using Nanopore Sequencing 93%
- Relating Standardized Automated Perimetry Performed with Stimulus Sizes III and V in Eyes With Field Loss due to Glaucoma and NAION 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.